On January 6, the U.S. Food and Drug Administration (FDA) granted the first waiver to allow a nucleic acid-based test, the Alere i Influenza A & B test, to be used in a greater variety of healthcare settings. The test uses a nasal swab sample from a patient and provides results in as little as 15 minutes. Negative results don’t rule out influenza virus infection. Read more.
© 2022 HealthCom Media All rights reserved. No part of this website or publication may be reproduced, stored, or transmitted in any form or by any means, electronic or mechanical, including photocopy, recording, or any information storage and retrieval system, without permission in writing from the copyright holder.